Elidah
1 known investors
Elidah develops an FDA-cleared external neuromuscular therapy platform for treating urinary incontinence in women and men, offered through direct-to-consumer and clinical care channels including telehealth and Medicare coverage.
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AFeb 2024 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase I | 2018 | $150K |
| National Science Foundation | Phase II | 2016 | $750K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Elidah do?
- Elidah develops an FDA-cleared external neuromuscular therapy platform for treating urinary incontinence in women and men, offered through direct-to-consumer and clinical care channels including telehealth and Medicare coverage.
- Who are Elidah's investors?
- Elidah's investors include Connecticut Innovations.